Terumo Valuation

Is 4543 N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4543 N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4543 N (MX$391.96) is trading above our estimate of fair value (MX$262.09)

Significantly Below Fair Value: 4543 N is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4543 N?

Other financial metrics that can be useful for relative valuation.

4543 N key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.7x
Enterprise Value/EBITDA20.7x
PEG Ratio3.2x

Price to Earnings Ratio vs Peers

How does 4543 N's PE Ratio compare to its peers?

The above table shows the PE ratio for 4543 N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.2x
RMD ResMed
31x11.1%US$36.3b
DXCM DexCom
41.6x16.8%US$29.0b
IDXX IDEXX Laboratories
40.6x9.9%US$34.9b
SOON Sonova Holding
31.5x8.6%CHF 18.9b
4543 N Terumo
37.6x11.8%Mex$4.6t

Price-To-Earnings vs Peers: 4543 N is expensive based on its Price-To-Earnings Ratio (37.6x) compared to the peer average (36.8x).


Price to Earnings Ratio vs Industry

How does 4543 N's PE Ratio compare vs other companies in the Global Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a0%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a0%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 4543 N is expensive based on its Price-To-Earnings Ratio (37.6x) compared to the Global Medical Equipment industry average (28.7x).


Price to Earnings Ratio vs Fair Ratio

What is 4543 N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4543 N PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4543 N's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4543 N forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
Mex$435.98
0%
9.9%Mex$503.24Mex$331.08n/a14
Nov ’25Mex$391.96
Mex$433.43
+10.6%
9.8%Mex$492.79Mex$332.97n/a14
Oct ’25n/a
Mex$438.25
0%
10.0%Mex$498.82Mex$337.04n/a14
Sep ’25n/a
Mex$433.09
0%
10.4%Mex$498.36Mex$336.73n/a13
Aug ’25n/a
Mex$380.09
0%
10.3%Mex$435.35Mex$302.33n/a13
Jul ’25n/a
Mex$361.13
0%
10.3%Mex$420.31Mex$291.89n/a13
Jun ’25n/a
Mex$333.92
0%
10.5%Mex$390.10Mex$270.90n/a13
May ’25n/a
Mex$319.82
0%
12.6%Mex$384.76Mex$265.54n/a12
Apr ’25n/a
Mex$332.10
0%
13.2%Mex$403.81Mex$278.69n/a12
Mar ’25n/a
Mex$324.30
0%
12.9%Mex$402.37Mex$277.69n/a12
Feb ’25n/a
Mex$302.20
0%
9.1%Mex$362.41Mex$251.35n/a12
Jan ’25n/a
Mex$307.70
0%
11.4%Mex$387.14Mex$257.09n/a12
Dec ’24n/a
Mex$296.60
0%
10.5%Mex$374.80Mex$248.89n/a13
Nov ’24n/a
Mex$296.78
0%
13.1%Mex$390.70Mex$231.98Mex$391.9613
Oct ’24n/a
Mex$275.13
0%
9.9%Mex$311.80Mex$219.41n/a10
Sep ’24n/a
Mex$279.71
0%
10.2%Mex$318.99Mex$220.39n/a11
Aug ’24n/a
Mex$291.84
0%
9.0%Mex$329.11Mex$233.37n/a11
Jul ’24n/a
Mex$297.05
0%
10.5%Mex$340.37Mex$228.98n/a12
Jun ’24n/a
Mex$307.89
0%
15.6%Mex$429.98Mex$233.96n/a13
May ’24n/a
Mex$320.03
0%
16.8%Mex$448.70Mex$217.75n/a13
Apr ’24n/a
Mex$338.72
0%
17.5%Mex$487.71Mex$229.92n/a13
Mar ’24Mex$244.66
Mex$327.82
+34.0%
17.0%Mex$465.26Mex$219.34n/a14
Feb ’24Mex$271.33
Mex$369.59
+36.2%
12.8%Mex$498.29Mex$296.09n/a14
Jan ’24Mex$263.43
Mex$377.02
+43.1%
13.7%Mex$531.84Mex$305.99n/a14
Dec ’23n/a
Mex$360.23
0%
13.9%Mex$507.45Mex$298.91n/a14
Nov ’23n/a
Mex$353.14
0%
13.8%Mex$496.77Mex$292.62n/a14

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies